Dr. Daniel M. Berinstein co-authored a SCORE2 trial paper—published in a recent issue of JAMA Ophthalmology—that looked at patients receiving monthly injections vs. treat-and-extend regimens in a study of comparative treatments for Retinal Vein Occlusion. The multi-center, prospective, randomized trial, sponsored by the National Eye Institute (NEI), compared intravitreal bevacizumab (Avastin) to aflibercept (Eylea) for the treatment of Macular Edema secondary to Central Retinal Vein Occlusion (CRVO). Dr. Berinstein served as the Principal Investigator for RGW, which was one of approximately 80 participating sites.
